Medeon Biodesign, Inc. (6499.TWO)

42.90 +0.40 (+0.94%) At close: 01:30PM CST

Medeon Biodesign, Inc.

116, HouGang Street
7th Floor
Taipei 11170
Taiwan
886 2 2881 6686
https://www.medeonbio.com

Sector(s): Healthcare
Industry: Medical Instruments & Supplies
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Yue-Teh Jang Ph.D.	Chairman of the Board & CEO	823k	N/A	N/A
Dr. Jenny Chen	Spokesperson & CFO	N/A	N/A	N/A
Dr. Yi-Ju Chen	Executive Vice President	N/A	N/A	N/A
Ms. Greta Chang	Executive Vice President	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.

Description

Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in Taiwan and the United States. The company focuses on developing devices for minimally invasive surgeries, such as Duett, a vascular graft system; ClickClean, a solution to view throughout laparoscopic surgeries; AbClose to prevent port site herniation caused by improper closure; UroCross, an expander system; PUMA, a solution to treat orthopedic extremity injuries; and Cross-Seal, a large-bore closure device. It is involved in medical device contract manufacturing, equity investment and commerce of medical devices, manufacturing and sale of injection molding and components of medical devices. Medeon Biodesign, Inc. was incorporated in 2012 and is headquartered in Taipei, Taiwan.

Corporate governance

Medeon Biodesign, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.